2[2]Dienstag JL,Perrillo RP, Schiff ER,et al. A preliminary trial of Lamiv udine for chronic hepatitis B infection[J]. N Engl J Med, 1995,333:1675.
3[3]Schiff E, Cianciara J, Karayaicin, S, et al, The international lamivudine investigator group, Durable HbeAg and HbsAg seroconversion after lamivudine forchronic hepatitis B(abstr)[J]. J Hepatd,2000,32: 99.
4[4]Goodman Z, Dhinon AP, Wu PC, et al. Lamivudine treatment reduces, progression to cirrhosis in patients with chronic hepatitis B[J]. J Hepatol, 1999,30(S,) :59.
5[5]Liawy-F ,LeungNWY, ChangTT,et al. Effects of eotended Lami - vudine therapy in Asian patients with chronie hepatitis B[J]. Gastroenterology, 2000,119(7): 172.
6[6]Leung NWY, Lai Cl, ChangTT, et al. Three year Lamivudine therapy in chronic HBV [J] .J Hepatol, 1999,30(Si):59.
7[7]Chang TT, Lai Cl, Ljan YF,et al. Incremental increases in HbeAg seroconversion and continued ALT normalization in Asian chronic HBV patients treated with Lamivudine for four years [J] . Antiviral therapy, 2000,5: 44.
8[8]Liaw YF Chien RN, yeh CT, et al,Acute exacerbation and hepatitis B viru sclearance after emergence of YMDD motify mutation during Lamivudine therapy[J ]. Hepat ollgy, 1999,30(2) :567.
9[9]Allen MI ,Deslaurier SM, Tipples GA, et al. Identification and cheracterizati on of mutations in Hepatitis B virus resistant to Lamivudine [J]. Hepatology, 1998,27(6): 1670.
10[10]Heathcote EJ,Jeffers L, Wright T, et al. Loss of serum HBV DNA and HbeAg Ⅱ and seroconversion following short- term (12weeks)adefovir dipivoxil therapy in chronic hepatitis B: two placebo- controlled phase Ⅱ studies(abstr)[J]. Hepatolo gy, 1998,28:317A.
